On Dec. 30, 2020, Bausch Health announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland had granted an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4 mg/ml, for the treatment of COVID-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) who require oxygen therapy. DEXAVEN is a corticosteroid that reduces inflammation.